内部人交易雷达

美国 · SEC Form 4 · 快照日期： 2026-10-18 · 构建时间： 2026-10-18 · English

← 美国市场 · 覆盖记录

美国 · SEC FORM 4

Odyssey Therapeutics, Inc.

ODTX · Nasdaq · CIK 0001882782 · Healthcare · Biotechnology

内部人信号

84.2 / 100

7 位买方 · 9 条买入交易行 · $75.3M 买入总额

为什么有这个信号？

买方广度较强
买入规模较强
角色中等
近期性较低
确信度较强
评分构成

每条进度条表示其对当前分数的贡献；权重和公式保持不变。

Cluster+35.0 / 35
买入规模+24.5 / 25
角色+14.0 / 20
近期性+0.7 / 10
确信度+10.0 / 10

哪些因素限制了当前分数？

  • ⚠ 角色得分低 · 买入者中职位最高的是：Other（CEO、董事长和持股 10% 以上的股东得分最低）
  • ⚠ Purchase activity is becoming less recent
  • ✓ Cluster breadth is broad · 4+ insiders

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 按当前 180 天规则给合资格的股票买入打分。分数只表示研究的先后，不是收益预测或概率。回测没有显示美国分数越高、之后的表现越好。

内部人活动时间轴

申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。

AprMayJunJulAugSepOct
George Simeon; SR ONE CAPITAL MANAGEMENT, LLCTenPercentOwner
○●▼○
LEIDEN JEFFREY MDirector
●○○○
COULTER JAMES G; TPG GP A, LLC; WINKELRIED JONOther
○○●
Opipari Anthony W.See Remarks
○○○
Li Nan (LN)Director
○●
Dimension Capital II, L.P.Director
○●
● 买入▼ 卖出○ 其他

Showing the six most active owners; 3 additional owner(s) remain in Form 4 申报证据.

买方广度与集中度

合资格买方7
买入集中度33%最大买方： COULTER JAMES G; TPG GP A, LLC; WINKELRIED JON · $25.0M
聚集买入 · 15天7 insiders峰值活动： 2026-05-08–2026-05-11

Roles in the peak window: Chief Financial Officer, Director, Other, TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

信号历史

84.2 / 100

最新留档分数

→ +0.0 pts相对上一个留档快照
  1. 84.3
  2. 84.2
  3. 84.2
  4. 84.2
  5. 84.2

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

近期 Form 4 活动

9买入
3卖出
27其他 Form 4 交易行
9SEC 申报 · 365天
买入9 qualifying P line(s) · 180 days
卖出3 sale line(s) · 仅供背景
其他27 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

市场背景

市场背景补充近期价格表现与风险信息，不影响内部人信号。

价格表现

1M
-19.6%
3M
+7.9%
6M
—
12M
—

波动率与流动性

波动率
72.1%
Beta
—
平均每日成交额
USD 5.1M

估值

市值
USD 912.6M
P/E
—

基本面

利润率
—
ROE
—
细分行业
Biotechnology

市场数据

价格数据截至：2026-10-11 · 价格来源：OpenBB/yfinance; 成交量来自 本机价格缓存 (yfinance) · 来自 SEC 申报文件：市值 · 市值 = 申报文件封面所列的已发行股数 × 最新收盘价。股数日期：2026-06-12 · Status: PASS

空头余额

空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。

空头股数
3,105,465
上期报告
2,208,686
日均成交量
551,207
回补天数
5.6

FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。

历史股票买入

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting owner类型证券股数平均价格估算金额来源
2026-05-11COULTER JAMES G; TPG GP A, LLC; WINKELRIED JON买入 (P)Common Stock1,388,889USD 18.00USD 25,000,002SEC 申报 ↗
2026-05-11Li Nan (LN)买入 (P)Common Stock1,111,111USD 18.00USD 19,999,998SEC 申报 ↗
2026-05-11George Simeon; SR ONE CAPITAL MANAGEMENT, LLC买入 (P)Common Stock555,555USD 18.00USD 9,999,990SEC 申报 ↗
2026-05-11Chu Shelley买入 (P)Common Stock11,111USD 18.00USD 199,998SEC 申报 ↗
2026-05-08Dimension Capital II, L.P.买入 (P)Common Stock1,111,111USD 18.00USD 19,999,998SEC 申报 ↗
2026-05-08LEIDEN JEFFREY M买入 (P)Common Stock5,000USD 20.00USD 100,000SEC 申报 ↗
2026-05-08Haas Jason买入 (P)Common Stock1,000USD 20.00USD 20,000SEC 申报 ↗

Form 4 申报证据

39 transaction lines in the latest 365-day window; 39 in local history.

日期申报人类型证券股数平均价格估算金额来源
2026-05-11COULTER JAMES G; TPG GP A, LLC; WINKELRIED JON买入 (P)Common Stock1,388,889USD 18.00USD 25,000,002SEC 申报 ↗
2026-05-11COULTER JAMES G; TPG GP A, LLC; WINKELRIED JONJ (J)Common Stock425,462USD —USD —SEC 申报 ↗
2026-05-11COULTER JAMES G; TPG GP A, LLC; WINKELRIED JONC (C)Common Stock1,880,497USD —USD —SEC 申报 ↗
展开近期 Form 4 证据 (21 grouped rows)
日期申报人类型证券股数平均价格估算金额来源
2026-05-11COULTER JAMES G; TPG GP A, LLC; WINKELRIED JON买入 (P)Common Stock1,388,889USD 18.00USD 25,000,002SEC 申报 ↗
2026-05-11COULTER JAMES G; TPG GP A, LLC; WINKELRIED JONJ (J)Common Stock425,462USD —USD —SEC 申报 ↗
2026-05-11COULTER JAMES G; TPG GP A, LLC; WINKELRIED JONC (C)Common Stock1,880,497USD —USD —SEC 申报 ↗
2026-05-11Opipari Anthony W.期权行权／转换 (M)Common Stock541USD —USD —SEC 申报 ↗
2026-05-11Opipari Anthony W.代扣税 (F)Common Stock4USD 18.00USD 72SEC 申报 ↗
2026-05-11Opipari Anthony W.C (C)Common Stock6,965USD —USD —SEC 申报 ↗
2026-05-11Li Nan (LN)买入 (P)Common Stock1,111,111USD 18.00USD 19,999,998SEC 申报 ↗
2026-05-11Li Nan (LN)C (C)Common Stock1,709,543USD —USD —SEC 申报 ↗
2026-05-11LEIDEN JEFFREY M期权行权／转换 (M)Common Stock2,963USD —USD —SEC 申报 ↗
2026-05-11LEIDEN JEFFREY M代扣税 (F)Common Stock17USD 18.00USD 306SEC 申报 ↗
2026-05-11LEIDEN JEFFREY MC (C)Common Stock28,698USD —USD —SEC 申报 ↗
2026-05-11Glick Gary DC (C)Common Stock27,386USD —USD —SEC 申报 ↗
2026-05-11George Simeon; SR ONE CAPITAL MANAGEMENT, LLCX (X)Common Stock320,047USD —USD —SEC 申报 ↗
2026-05-11George Simeon; SR ONE CAPITAL MANAGEMENT, LLC卖出 (S)Common Stock1,780USD 18.00USD 32,040SEC 申报 ↗
2026-05-11George Simeon; SR ONE CAPITAL MANAGEMENT, LLC买入 (P)Common Stock555,555USD 18.00USD 9,999,990SEC 申报 ↗
2026-05-11George Simeon; SR ONE CAPITAL MANAGEMENT, LLCC (C)Common Stock2,921,061USD —USD —SEC 申报 ↗
2026-05-11Chu Shelley买入 (P)Common Stock11,111USD 18.00USD 199,998SEC 申报 ↗
2026-05-08Dimension Capital II, L.P.买入 (P)Common Stock1,111,111USD 18.00USD 19,999,998SEC 申报 ↗
2026-05-08Dimension Capital II, L.P.C (C)Common Stock1,709,543USD —USD —SEC 申报 ↗
2026-05-08LEIDEN JEFFREY M买入 (P)Common Stock5,000USD 20.00USD 100,000SEC 申报 ↗
2026-05-08Haas Jason买入 (P)Common Stock1,000USD 20.00USD 20,000SEC 申报 ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

快照与身份

快照日期2026-10-18
排名版本US-v1.2
数据质量PASS ELIGIBLE · —
股票代码ODTX
CIK0001882782
行业Healthcare
细分行业Biotechnology Yahoo Finance
SEC SIC2836 Biological Products, (No Diagnostic Substances)
交易所Nasdaq

数据覆盖

本地 Form 4 历史39 transaction lines from 2026-05-08 to 2026-05-11
9 P purchase lines · 3 S sale lines · 27 other lines
SEC 公司申报打开 SEC 申报 ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.